CTOs on the Move

Osteal Therapeutics

www.ostealtx.com

 
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ostealtx.com
  • 4835 Lyndon B Johnson Freeway Suite 520
    Dallas, TX USA 75244
  • Phone: 469.809.2630

Executives

Name Title Contact Details

Funding

Osteal Therapeutics raised $30M on 03/08/2022

Similar Companies

Santa Cruz Nutritionals

"Santa Cruz Nutritionals is the world's leading manufacturer of enhanced confectionery delivery systems for the functional food and supplement, or ""nutraceutical"" market. Using its unique food science expertise and proprietary processes the company has"

Boston Health Care for the Homeless Program

Since its founding in 1985, Boston Health Care for the Homeless Program has been guided by a simple mission - to provide and assure access to the highest quality health care for Bostons homeless men, women and children. http://www.bhchp.org

video king inc

video king inc is a Elkton, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Care Network

We would love to hear from you! Please private message us with questions or feedback and we will respond as quickly as possible. General guidelines for posting on our page: • Be humane: Behind the computer screen, there are real humans with real fee...

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.